TransMedics Group, Inc. (NASDAQ:TMDX) Director Sells $1,600,707.20 in Stock

TransMedics Group, Inc. (NASDAQ:TMDX) Director James R. Tobin sold 15,040 shares of the business’s stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $106.43, for a total transaction of $1,600,707.20. Following the transaction, the director now owns 205,171 shares in the company, valued at approximately $21,836,349.53. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

TransMedics Group Trading Up 2.9 %

NASDAQ TMDX opened at $127.99 on Monday. The company’s 50-day moving average price is $85.54 and its 200-day moving average price is $77.32. The company has a current ratio of 9.30, a quick ratio of 8.49 and a debt-to-equity ratio of 3.69. The stock has a market cap of $4.19 billion, a PE ratio of -376.44 and a beta of 1.87. TransMedics Group, Inc. has a 12 month low of $36.42 and a 12 month high of $129.66.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Tuesday, April 30th. The company reported $0.35 EPS for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.40. The business had revenue of $96.90 million for the quarter, compared to the consensus estimate of $83.78 million. TransMedics Group had a negative net margin of 3.43% and a positive return on equity of 8.29%. The company’s revenue for the quarter was up 132.9% on a year-over-year basis. During the same quarter last year, the firm posted ($0.08) EPS. Equities research analysts forecast that TransMedics Group, Inc. will post 0.62 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in TMDX. FMR LLC increased its position in TransMedics Group by 42.5% during the 3rd quarter. FMR LLC now owns 4,714,870 shares of the company’s stock valued at $258,139,000 after purchasing an additional 1,407,171 shares during the period. Eventide Asset Management LLC increased its position in TransMedics Group by 1,271.7% during the 3rd quarter. Eventide Asset Management LLC now owns 925,356 shares of the company’s stock valued at $50,663,000 after purchasing an additional 857,895 shares during the period. Mackenzie Financial Corp purchased a new position in TransMedics Group during the 4th quarter valued at about $35,804,000. Wasatch Advisors LP purchased a new position in TransMedics Group during the 1st quarter valued at about $32,162,000. Finally, Bank of New York Mellon Corp boosted its holdings in shares of TransMedics Group by 91.4% in the 3rd quarter. Bank of New York Mellon Corp now owns 760,099 shares of the company’s stock valued at $41,615,000 after buying an additional 363,012 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on TMDX. TD Cowen boosted their price objective on shares of TransMedics Group from $100.00 to $130.00 and gave the company a “buy” rating in a research report on Wednesday, May 1st. Piper Sandler reiterated an “overweight” rating and set a $120.00 price objective (up previously from $95.00) on shares of TransMedics Group in a research report on Wednesday, May 1st. Oppenheimer upped their price target on shares of TransMedics Group from $105.00 to $125.00 and gave the stock an “outperform” rating in a report on Wednesday, May 1st. JPMorgan Chase & Co. upped their price target on shares of TransMedics Group from $105.00 to $127.00 and gave the stock an “overweight” rating in a report on Wednesday, May 1st. Finally, Canaccord Genuity Group upped their price target on shares of TransMedics Group from $102.00 to $117.00 and gave the stock a “buy” rating in a report on Wednesday, May 1st. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $119.00.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.